Pharmaceutical - AstraZeneca, Antibiotics and Infectious diseases

Filter

Popular Filters

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research

28-01-2014

Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations

22-11-2013

At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

05-11-2013

Two units under Singapore’s Agency for Science, Technology and Research (A*STAR) have signed a joint…

A*STARAntibiotics and Infectious diseasesAstraZenecaPharmaceuticalResearch

Antibiotic ceftaroline fosamil shows promise for treating MRSA pneumonia

12-09-2013

A drug approved just two years ago for treating bacterial infections may hold promise for treating the…

Antibiotics and Infectious diseasesAstraZenecaceftaroline fosamilForest LaboratoriesPharmaceuticalResearchTeflaroZinforo

AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics

18-12-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced yesterday that a combined panel of experts…

Antibiotics and Infectious diseasesAstraZenecaBrilintaCardio-vascularLicensingMedImmunePharmaceuticalProgenics PharmaceuticalsRegulation

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

04-12-2012

USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor

08-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

Pharmaceutical majors unite in Japan to combat H. pylori

18-09-2012

On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

AstraZeneca poaches Roche exec as CEO; Gets EU approval for Zinforo

28-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning revealed that Pascal Soriot from rival Switzerland-based…

Antibiotics and Infectious diseasesAstraZenecaEuropeManagementPharmaceuticalRegulationRocheZinforo

AstraZeneca/BTG abandon CytoFab for sepsis as it fails in Ph IIb

09-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has decided to halt any further development of AZD9773…

Antibiotics and Infectious diseasesAstraZenecaBTGCytoFabLicensingPharmaceuticalResearch

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI

18-10-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Company Spotlight

ImmunoGen

ImmunoGen

Back to top